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Abstract
Metabolic and storage diseases constitute a heterogeneous
group of disorders that occur in the setting of altered biochem-
ical homeostasis. Many of these disorders affect the lungs,
either exclusively or as part of a systemic syndrome. For
example, amyloidosis can be limited to the tracheobronchial
tree or involve the kidneys, lungs and heart. The indolent
course of some of these disorders and the non-specific clinical
symptoms often result in a diagnostic challenge. Imaging,
particularly high-resolution computed tomography (HRCT),
is an invaluable asset in the diagnosis of these clinical condi-
tions. Somemetabolic and storage diseases have characteristic
HRCTappearances, helping narrow the differential diagnosis.
Correlation of the radiological and histopathological findings
of this group of diseases has also helped improve understand-
ing of these disorders. In addition, CT can offer guidance
when tissue sampling is warranted and aid in histopathologi-
cal diagnosis. This article describes the pertinent clinical fea-
tures of the more common metabolic and storage diseases
affecting the lungs, illustrates their respective HRCT findings
and provides the relevant differential diagnosis.
Teaching Points
• To recognise the various metabolic and storage lung diseases
• To identify the characteristic imaging findings in various
metabolic and storage lung diseases
• To discuss the relevant differential diagnoses of each of these
diseases
Keywords Metabolic lung disease . Storage lung disease .
Chest radiography . Computed tomography
Introduction
Metabolic and storage diseases are a diverse group of condi-
tions that are characterised by underlying biochemical or
metabolic dysfunctions.Most of these diseases are uncommon
or rare. Pulmonary disease in affected patients is most com-
monly a facet of systemic disease. The more common meta-
bolic lung diseases include pulmonary calcification and ossi-
fication, pulmonary alveolar microlithiasis, pulmonary amy-
loidosis and pulmonary alveolar proteinosis (PAP). Storage
diseases are rare inmost clinical practices, and patients usually
present with multiorgan involvement. Pulmonary involve-
ment in storage diseases occurs in Niemann-Pick disease,
Gaucher disease and Hermansky-Pudlak syndrome.
In this review, we describe the radiographic and high-
resolution computerised tomography (HRCT) findings of the-
se disorders and include discussion of pathophysiology, per-
tinent clinical features and the relevant different diagnosis.
The key features of these metabolic and storage disorders are
summarised in Tables 1 and 2, emphasising the value of
clinical-radiological correlation in reaching an accurate diag-
nosis. Knowledge of these diseases and their respective imag-
ing appearances is important for radiologists and clinicians,
particularly those involved in respiratory care.
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Metabolic lung diseases
HRCT technique
In patients with suspected metabolic or storage lung disease,
HRCT should be done as a helical acquisition at end inspira-
tion using the thinnest collimation and reconstructed at 1.0– to
1.5-mm slice thickness. The scan length should extend from
the thoracic inlet down to the diaphragms. A high-spatial
frequency kernel should be used for lung images. Contrast
administration is not necessary. Technique should be standard
for chest CT (typically 120 kVand automatic exposure control
for mA). If significant air trapping is suspected, limited expi-
ratory images can be obtained at 20-mm intervals from the
apex to the diaphragm.
Pulmonary calcification and ossification
Introduction and clinical features
Pulmonary calcification and ossification are the most common
metabolic lung diseases detected on chest radiography and
HRCT. Pulmonary calcification occurs either through dystro-
phic or metastatic mechanisms [1]. Dystrophic calcifications
form in damaged areas of lung as a result of inflammation or
infection, such as tuberculosis, or in areas of previous
haemorrhage or infarct. Calcification can also form in neo-
plasms such as chondrosarcoma or osteosarcoma as a natural
process of the disease [2]. Metastatic pulmonary calcification
develops in areas of normal lung in patients with altered
calcium and phosphate metabolism, leading to calcium depo-
sition in the lungs and other organs such as bones and kidneys.
Hypercalcaemia secondary to chronic renal failure (Fig. 1) is
the most common cause of metastatic pulmonary calcification
[3]. Other causes include primary hyperparathyroidism, skel-
etal metastases and multiple myeloma [4]. The various causes
are summarised in Table 3.
Diffuse pulmonary ossification has been increasingly
recognised since the advent of CT [5]. Pathologically, pulmo-
nary ossification can be classified as either nodular (NPO) or
Table 2 Summary of storage lung diseases
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Fig. 1 A 65-year-old woman with metastatic calcification from chronic
kidney failure. a AP radiograph shows dense foci of consolidation
(arrows) in the lower lungs. b , c Unenhanced CT images show mass-
like foci of calcified lung (arrows)
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dendriform (DPO) based on the respective morphological
appearances. Of the two entities, NPO is more common [6].
Nodular pulmonary ossification
Classically described with long-standing severe mitral steno-
sis, NPO can occur with any condition, leading to chronic
pulmonary oedema and pulmonary venous hypertension [7,
8]. Histologically, NPO is characterised by calcified or ossi-
fied intra-alveolar masses that are usually devoid of marrow
elements or fat [6].
Imaging findings
On radiography HRCT, small, discrete, round calcified nod-
ules 1–5 mm in diameter are present in the mid to lower lungs
(Fig. 2) [6]. The differential diagnosis in these patients in-
cludes healed varicella infection or remote disseminated gran-
ulomatous infections such as histoplasmosis.
Dendriform pulmonary ossification
Although the exact pathogenesis of DPO is unclear, the condi-
tion is postulated to be a reaction to chronic lung insult, resulting
in metaplasia of pulmonary fibroblasts into bone. In contrast to
NPO, DPO predominantly affects the alveolar interstitium and
usually contains marrow or fat elements [6]. DPO commonly
develops in the setting of chronic inflammation, including inter-
stitial fibrosis, and may also be seen in patients with a history of
amyloidosis, cystic fibrosis, asbestos exposure or treatment with
busulfan [9–12]. In the authors’ experience, recurrent aspiration
also appears to be a risk factor. DPO is most common in men in
their fifth and sixth decades of life. The clinical course is usually
indolent or slowly progressive [13].
Imaging findings
The chest radiographic findings of DPO include delicate
branching linear opacities and small distinct nodules. The differ-
ential diagnosis based on radiography includes fibrosis, bronchi-
ectasis and lymphangitic spread of tumour. HRCT findings are
quite characteristic, consisting of lower lobe predominant
Table 3 Causes of pulmonary calcification and ossification
Pulmonary calcification
(A) Dystrophic
1. Granulomatous diseases—granulomatous infection such as histoplasmosis and tuberculosis and non-infectious causes such as sarcoidosis.
2. Other infections—viral infections such as varicella and parasitic infections such as paragonimiasis.
3. Occupational lung diseases—silicosis, coal workers’ pneumoconiosis.
4. Metabolic lung diseases—amyloidosis, Pulmonary alveolar microlithiasis.
5. Vascular causes—areas of prior haemorrhage or infarction, pulmonary hypertension, arterio-venous malformation.
6. Miscellaneous—post-treatment such as radiation therapy.
(B) Metastatic
1. Non-neoplastic—most common cause is hypercalcaemia in the setting of chronic renal failure. Other causes are conditions causing primary
hyperparathyroidism, iatrogenic (following calcium therapy), Paget’s disease.
2. Neoplastic—parathyroid carcinoma, multiple myeloma, lymphoma/leukaemia and metastases such as chondrosarcoma.
Pulmonary ossification
1. Nodular type—in chronic venous congestion.
2. Dendriform type—in chronic lung insult with resultant fibrosis.
3. Bone forming neoplasms such as osteosarcoma.
Fig. 2 A 54-year-old man with fibrosing mediastinitis, mitral valve ste-
nosis and nodular pulmonary ossification. a Unenhanced HRCT image
shows high attenuation ground-glass opacities in the right upper and lower
lobes with punctate calcifications (arrowheads). b Unenhanced HRCT
image shows soft tissue thickening and dense calcification (arrow) at the
confluence of the right pulmonary veins
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punctate and serpentine calcifications (Figs. 3, 4), often located
in areas of co-existing lung disease such as fibrosis [11, 12].
Both NPO and DPO can show uptake of bone scanning
agent (e.g. technetium-99m methylene diphosphonate) [14].
Definitive diagnosis and treatment
Since this disorder is usually incidentally detected and affect-
ed patients are asymptomatic, no treatment is recommended.
Surveillance with pulmonary function tests or chest radiogra-
phy may be considered, if deemed necessary.
Pulmonary alveolar microlithiasis
Introduction and clinical features
Pulmonary alveolar microlithiasis is a rare disease characterised
by intra-alveolar deposition of microliths, which consist primar-
ily of calcium and phosphorous [15]. The aetiology is unknown,
although recent studies have found an autosomal recessive trait
caused by mutations of the SLC34A2 gene in affected patients
[16]. Pulmonary alveolar microlithiasis occurs in all age groups.
Most patients are asymptomatic, and the diagnosis is established
during imaging studies for other conditions.
Imaging findings
On radiography, diffuse calcified micronodules are present in
both lungs, leading to a “sandstorm” appearance [17]. These
nodules are most prevalent in the mid to lower lungs, likely
because of the increased surface area and blood supply [18, 19].
Interstitial thickening can also present, although this finding is
clearer on HRCT. Radiography may also show a lucent
subpleural line reflecting extrapleural fat between the ribs and
the calcified lung, described as “the black pleura sign” [20].
HRCT shows discrete calcified micronodules scattered
throughout the lungs. Apparent interlobular septal thickening
and calcification may also be present (Fig. 5), presumably the
result of increased concentration of microliths in the periphery
of the secondary pulmonary lobule [21, 22]. Pleural and
pericardial calcification has also been described [18, 23].
The differential diagnosis includes PAP, sarcoidosis, pneumo-
coniosis, idiopathic pulmonary haemosiderosis, amyloidosis
and metastatic calcification [24, 25].
Bone scintigraphy can demonstrate radiotracer uptake in
the lungs [26], and magnetic resonance imaging (MRI) can
show increased signal intensity of the lesions on T1-weighted
images [20].
Definitive diagnosis and treatment
Pulmonary alveolar microlithiasis can be definitively diag-
nosed through bronchoalveolar lavage or lung biopsy. There
is no effective treatment for this condition, and prognosis is
generally poor, with most patients experiencing worsening
respiratory insufficiency [18]. Lung transplantation may be
performed, although the long-term benefits are uncertain.
Fig. 3 A 48-year-old man with dendriform pulmonary ossification.
HRCT image shows branching and punctate calcifications (arrowheads)
in the right middle and lower lobes. There is a background of mild
reticulation and ground-glass opacity, reflecting underlying mild intersti-
tial fibrosis
Fig. 4 A man with asbestosis and dendriform pulmonary ossification.
Prone HRCT image shows branching calcifications (arrows) in both
lower lobes
Fig. 5 Amanwith pulmonary alveolar microlithiasis. Contrast-enhanced
HRCT image shows diffuse high attenuation ground-glass opacity with
superimposed septal lines (crazy-paving) (arrowheads) as well as foci of
calcified lung consolidation (arrows). Courtesy of Gerald F. Abbott,
M.D. (Boston, MA)
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Pulmonary amyloidosis
Introduction and clinical features
Amyloidosis comprises a diverse group of metabolic disorders
characterised by extracellular deposition of insoluble proteins
consisting of beta-pleated sheets. Clinically, amyloidosis can be
classified as either systemic or localised [27]. Systemic forms
of amyloidosis include primary amyloidosis, secondary amy-
loidosis and familial amyloidosis. Primary amyloidosis occurs
in the absence of pre-existing disease, with the exception of
dyscrasias (e.g. multiple myeloma and Waldenström macro-
globulinemia). Secondary amyloidosis, which is the more com-
mon form, results from a number of conditions, such as chronic
renal failure, chronic infection and neoplasia. Localised forms
are characterised by local production of fibrillar proteins (usu-
ally amyloid light chain [AL] type), which can be deposited in
nearly any organ. Familial amyloidosis typically presents as
sensorimotor peripheral neuropathy in the second or third
decade of life [28]. The kidneys and heart can also be involved.
In familial cardiac amyloidosis, the amyloid fibrils consist of
prealbumin, a mutant of transthyretin.
Respiratory tract involvement occurs in approximately 50%
of patients with amyloidosis and is more common with the
systemic form [27]. Clinical signs and symptoms vary
depending on whether the disease is systemic or localised.
The most common form of systemic amyloidosis, the AL form,
is seen in patients over 50 years of age [29]. In this form, the
clinical manifestations are variable as a result of multiorgan
involvement, and patients may often present with non-specific
symptoms such as fatigue or weight loss [30]. A substantial
number of patients also have cardiac involvement that may
contribute to respiratory symptoms such as dyspnea. Localised
amyloidosis with involvement of the tracheobronchial system
typically occurs in the fifth to sixth decades of life, and affected
patients may present with stridor and dyspnea [31].
Imaging findings
Three CT patterns of pulmonary amyloidosis have been de-
scribed: tracheobronchial, nodular parenchymal and diffuse
interstitial forms.
Tracheobronchial form
The most common is the tracheobronchial form, which is
characterised by submucosal deposition of fibrillar protein
within the airway wall. This can manifest on CT as nodules,
plaques or circumferential wall thickening [32, 33]. The lar-
ynx, trachea, and larger bronchi (Figs. 6, 7) may be involved.
With this form, metaplastic calcification of the nodules is
fairly common. Complications such as atelectasis and pneu-
monia are fairly common and are largely dependent on the site
of involvement. In one study, obstructive symptoms were
noted in patients with upper tracheal disease, whereas those
with mid-tracheal and distal airway disease presented with
recurrent pneumonias or lobar or distal atelectasis [31]. Also,
patients with distal airway involvement may develop second-
ary bronchiectasis [31].
A significant advantage of HRCT in evaluation of tracheo-
bronchial amyloidosis is the ability to accurately assess the
degree of luminal narrowing. Using volumetric acquisitions
and multiplanar reconstructions, airway luminal diameters
and areas and extent of wall thickening can be accurately
assessed. Also, HRCT can be used to guide bronchoscopic
sampling and identify sites for treatment.
The differential diagnosis is limited and includes diffuse
tracheal diseases such as relapsing polychondritis, granuloma-
tosis with polyangitis, sarcoidosis and inflammatory bowel
disease [34–37]. In contrast to other diffuse tracheal diseases,
relapsing polychondritis characteristically spares the posterior
tracheal and bronchial membranes. Tracheobronchopathia
Fig. 6 A 61-year-old man with tracheobronchial amyloidosis. Axial (a)
and coronal reformatted (b) CT images show circumferential, diffuse
tracheobronchial thickening with foci of mural calcification (arrow-
heads) and resultant luminal narrowing
Fig. 7 A man with tracheobronchial amyloidosis. HRCT image shows
diffuse bronchial wall thickening with mural calcifications (arrows) and
resultant luminal narrowing. There are patchy linear foci of consolidation
(arrowhead) in the left upper lobe resulting from obstructive pneumonia
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osteochondroplastica (TBO) is an uncommon condition
characterised by formation of osseous, cartilaginous or both
types of nodules within the large airways, and some reports in
the literature have suggested that TBOmay be associated with
tracheobronchial amyloidosis [38]. As with relapsing
polychondritis, TBO also spares the posterior airway
membrane.
Nodular parenchymal form
Nodular parenchymal amyloidosis is relatively rare, with one
study reporting only seven cases of nodular disease over a 13-
year period [27]. It is characterised by solitary or multiple well-
defined, predominantly subpleural nodulesmeasuring up to 5 cm
(Figs. 8, 9) [39]. These nodules are smoothly marginated and
usually are slow growing. Cavitation may occur. As with the
tracheobronchial form, calcification within the nodules is fairly
common and is well depicted on HRCT [40]. The differential
diagnosis is broad and includes granulomatous infection or neo-
plasia. An associationwith Sjögren syndrome has been described
[41]. In these patients, HRCT can be helpful in assessing the
nodules, as well as other manifestations such as randomly
scattered cysts, bronchial wall thickening and bronchiectasis
[42] (Fig. 10). Rarely, cystic lung disease can be seen in the
absence of Sjögren syndrome (Fig. 11).
Diffuse interstitial form
Diffuse interstitial amyloidosis is the most rare form and is
characterised by deposition of amyloid in the pulmonary
interstitium. Most affected patients have systemic amyloid-
osis. HRCT findings in patients with this condition include
reticulation and septal thickening (Fig. 12). Calcified or non-
calcified micronodules may also be present [42]. Differential
considerations include interstitial lung disease and neoplastic
diseases including lymphangitic carcinomatosis.
Miscellaneous findings
Mediastinal and hilar lymph node enlargement can occur in
isolation or as a component of systemic amyloidosis (Figs. 8b
and 13) [27, 42]. Pleural involvement has also been reported,
Fig. 8 A 54-year-old man with nodular parenchymal amyloidosis. a
Coronal reformatted HRCT image shows scattered punctate calcifications
(arrowheads) in both lungs with patchy consolidation (arrows) in the
right lung. In addition, a moderate right pleural effusion is noted. b Axial
HRCT image shows punctate calcifications (arrowheads) in the lungs, a
small right pleural effusion, and right paratracheal lymphadenopathy
(arrow)
Fig. 9 Amanwith nodular parenchymal amyloidosis. Contrast enhanced
CT shows multiple calcified nodules (arrows) and dense left lower lobe
consolidation
Fig. 10 A man with Sjögren syndrome and amyloidosis. HRCT image
shows multiple cysts (arrows) in both lower lobes, scattered nodules
(arrowheads), and right lower lobe consolidation. The appearance is
similar to that of lymphoid interstitial pneumonia, and the two processes
may coexist in the setting of Sjögren syndrome
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manifesting as pleural thickening and persistent pleural effu-
sions (Fig. 12) [43].
Functional imaging with fluorodeoxyglucose-positron
emission tomography (FDG-PET) and amyloid scintigraphy
with technetium-aprotinin has been shown to highlight areas
of amyloid deposition, although the exact role of these tech-
niques is still uncertain [44, 45].
Definitive diagnosis and treatment
The reference standard for diagnosing amyloidosis is histopath-
ological confirmation of amyloid with Congo Red staining
under cross-polarised light; with this staining, amyloid demon-
strates apple-green birefringence [46]. Treatment and prognosis
depend on the type and distribution of the disease, with local-
ised forms usually managed conservatively and systemic forms
treated with chemotherapy and anti-inflammatory agents.
Patients with tracheobronchial disease may be treated with
debulking or excision of the lesion(s).
Pulmonary alveolar proteinosis
Introduction and clinical features
PAP is a rare disease characterised by accumulation of surfactant-
like material in the alveoli. The estimated incidence and preva-
lence of PAP is 3.7 per 1 million persons [47]. In patients with
this disease, mutations in the surfactant protein or granulocyte-
macrophage colony-stimulating factor (GM-CSF) genes result in
defective clearance of surfactant by alveolar macrophages [48].
Three forms of PAP are recognised: autoimmune, secondary and
genetic. The autoimmune type (previously called primary or
idiopathic) accounts for 90 % of all cases [49]. The more rare
secondary form is usually associated with haematological malig-
nancies and inhalation of toxins such as silica dust. The genetic
type is exceedingly rare. In the autoimmune and secondary
forms, clinical symptoms are non-specific, and nearly one-third
of affected patients are asymptomatic. Most patients with PAP
are young to middle-aged men [50]. An association of PAP with
smoking has been described [50], and superimposed infections
with Nocardia, Pneumocystis jiroveci and Mycobacteria have
been reported [50, 51].
Imaging findings
Imaging findings of PAP can be striking; and the clinicoradiologic
discordance with modest clinical symptoms and florid imaging
findings has been described [48]. Chest radiography is a helpful
initial imaging test for assessing patients with known or suspected
PAP. Radiography typically shows bilateral patchy opacities with
Fig. 11 A man with amyloidosis presenting as cystic lung disease.
HRCT image shows multiple cysts (arrows ) and scattered irregular
calcified nodules (arrowheads)
Fig. 12 Aman with diffuse interstitial amyloidosis. HRCT image shows
smooth interlobular septal thickening (arrow), predominantly in the right
lung. The small right pleural effusion (arrowhead) is related to proven
pleural amyloid deposition
Fig. 13 A man with lymph node amyloidosis. Contrast-enhanced CT
image shows bulky calcified mediastinal lymph node enlargement with
severe mass effect on the superior vena cava, leading to development of
venous collaterals
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a perihilar to basal predominance (Fig. 14). The pattern is non-
specific and can be easily mistaken for oedema and infection.
However, ancillary findings associated with pulmonary oedema
such as cardiomegaly and pleural effusion are usually absent. The
onset of symptoms can also be used to distinguish PAP from
pulmonary oedema, as PAP has an insidious onset, whereas
pulmonary oedema and infection typically develop rapidly.
HRCT is the imaging test of choice for known or suspected
PAP. The characteristic HRCT findings for PAP are patchy or
geographic areas of ground-glass opacity with superimposed
septal lines, termed “crazy-paving” (Figs. 14, 15) [52]. Al-
though crazy-paving in and of itself is a non-specific finding,
a geographic distribution in the correct clinical setting is
virtually pathognomonic for PAP. One series reviewed the
imaging findings of 98 patients with PAP [53]. Of the 89
patients who underwent chest radiography, 57 (58 %) had a
perihilar distribution of disease, with costophrenic and apical
sparing in 65 (73 %) patients. Of the 28 patients who
underwent CT, crazy-paving was present in 20 (71 %) patients,
and geographic or lobular areas of sparing were present in 15
(75 %) patients with the crazy-paving. Some reports describe
coexisting interstitial fibrosis in patients with PAP [54, 55].
FDG-PET has been shown to show FDG uptake in PAP
and is likely related to increased glucose utilisation in the
inflammatory component [56].
Definitive diagnosis and treatment
PAP is definitively diagnosed by staining bronchoalveolar la-
vage fluid, and lung biopsy is rarely required. Treatment de-
pends on the type of PAP.Whole-lung lavage is the treatment of
choice for symptomatic patients with autoimmune disease [48],
and secondary cases require removal of the inciting agent.
Experimental therapies with granulocyte-macrophage colony-
stimulating factor and rituximab have been tried and have been
successful in a subset of patients [57, 58].
Fig. 14 A 41-year-old woman with pulmonary alveolar proteinosis. a
PA chest radiograph shows patchy hazy opacities with some foci of more
confluent opacity (arrows). b , c HRCT images show a geographic
pattern of ground-glass opacity and superimposed septal lines (“crazy-
paving”)
Fig. 15 A man with pulmonary alveolar proteinosis. Axial (a) and
coronal reformatted (b) HRCT images show a more diffuse pattern of
crazy-paving
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Storage lung diseases
Gaucher disease
Introduction and clinical features
Gaucher disease, the most common lysosomal storage disor-
der, results from deficiency of the enzyme glucocerebrosidase
[59]. Although this condition is rare worldwide, occurring in
approximately 1 per 75,000 births, it occurs most frequently
among Ashkenazi Jews [60]. Gaucher disease leads to the
accumulation of lipid-laden macrophages (Gaucher cells) in
a number of organs, particularly the liver, spleen, bone mar-
row and lung. Lung involvement is variable, although it has
been reported in severe forms of the disease [61].
Imaging findings
When the interstitium is infiltrated with Gaucher cells, septal
thickening may be present on HRCT (Fig. 16) [62]. A
desquamative interstitial pneumonia-like reaction has also
been described secondary to alveolar filling with Gaucher
cells [63]. Plugging of the capillary walls can result in the
pulmonary hypertension [64]. Furthermore, long-standing liv-
er disease may predispose the patient to hepatopulmonary
syndrome with intrapulmonary vascular dilation and arterio-
venous shunting [65].
Definitive diagnosis and treatment
Bronchoalveolar lavage or lung biopsy can be used for defin-
itive diagnosis of lung involvement. In general, prognosis is
poor, with more than half of patients dying of respiratory
failure. Possible therapeutic options include enzyme therapy
and substrate reduction therapy [66]. Patients with
hepatopulmonary syndrome may have a worse prognosis [67].
Niemann-Pick disease
Introduction and clinical features
Niemann-Pick disease refers to a group of rare autosomal
recessive lysosomal storage disorders that are subclassified into
types A, B, and C. Type A is the most common and has a high
incidence in Ashkenazi Jews, where the carrier frequency is
approximately 1 per 100 persons [60]. Types A and B are
caused by absence or deficiency of sphingomyelinase, respec-
tively. Patients with Type A usually die within a few years of
birth, while type B patients with residual enzyme activity often
survive into adulthood [68]. Type C disease is caused by
mutations of NPC1 and NPC2 genes, which code for trans-
membrane proteins involved in Golgi shuttling and cholesterol
binding [68]. Lung involvement typically occurs in all forms of
the disease, with the possible exception of the adult form (type
C) [69]. In patients with Niemann-Pick disease, lipid-laden
macrophages called Niemann-Pick cells are deposited in vari-
ous organs, including the lungs. In the lung, these cells infiltrate
into and are deposited in the alveolar walls and interstitium
with relative preservation of pulmonary architecture [68]. Most
patients with this disease present during infancy [70].
Imaging findings
On HRCT, ground-glass opacity predominates in the upper
lungs and interlobular septal thickening predominates in the
lung bases (Fig. 17) with preservation of underlying lung
architecture. Ground-glass opacity may reflect an endogenous
lipoid pneumonia with partial alveolar filling (Fig. 18) [71],
although the exact cause for the distribution of these findings
is unclear [72].
Definitive diagnosis and treatment
Bronchoalveolar lavage or lung biopsy can be used to dem-
onstrate lung involvement by demonstrating the presence of
characteristic Niemann-Pick cells. Treatment is generally sup-
portive, although some reports have demonstrated the value of
whole lung lavage in treating endogenous lipoid pneumonia
[72]. Also, haematopoietic stem cell transplantation has been
reported to be successful in treating lung disease [70].
Hermansky-Pudlak syndrome
Introduction and clinical features
Hermansky-Pudlak syndrome (HPS) comprises a group of
autosomal recessive disorders characterised by a triad of
oculocutaneous albinism, platelet dysfunction with bleeding
diathesis, and pulmonary disease [73]. Although this syndrome
is rare worldwide, it has the highest prevalence in northwest
Fig. 16 A child with Gaucher disease. HRCT images shows fine linear
opacities and hilar lymph node enlargement (arrowheads). Courtesy of
Alan Brody, M.D. (Cincinnati, OH)
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Puerto Rico, affecting approximately 1 in 1,800 persons [74].
Seven different genes associated with HPS have been identified
in humans [75]. The fundamental pathophysiology of this
disease is disturbed formation or trafficking of intracellular
vesicles such as lysosomes and melanosomes, resulting in
intracellular accumulation of ceroid-lipofuscin [76]. Lung in-
volvement in HPS is typically characterised by progressive
pulmonary fibrosis. The cause of fibrosis is unclear, although
it has been postulated to result from sequential injury to alve-
olar epithelium with the formation of lamellar bodies [77].
Specifically, researchers have explored the role of type II
pneumocytes in this pathology [78].
Imaging findings
On HRCT, HPS manifests as reticulation, septal thickening, and
ground-glass opacities, all of which can progress over time
(Fig. 19). In advanced cases, peribronchovascular interstitial
thickening has also been described [79]. A usual interstitial
pneumonia pattern is typically present on histopathology [75].
Fig. 19 A 53-year-old man with Hermansky-Pudlak syndrome. a , b
HRCT images show reticulation (arrowheads) and traction bronchiecta-
sis (arrows) on a background of diffuse ground-glass opacity
Fig. 18 A man with Niemann-Pick disease. a , b Contrast-enhanced CT
images show extensive ground-glass opacity. Mild septal thickening
(arrows) is also present
Fig. 17 A 46-year-old woman with Niemann-Pick disease. a HRCT
image shows ground-glass opacity with septal thickening (arrowheads)
in the upper lobes. Small pleural effusions are present. b HRCT image
inferiorly at the level of heart again shows ground-glass opacity with
septal thickening (arrowheads). Also seen are bilateral small pleural
effusions and adjacent atelectasis (arrow)
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Definitive diagnosis and treatment
Prognosis is poor in patients with lung fibrosis. There is no
effective therapy for pulmonary fibrosis, although lung trans-
plantation has been performed in selected patients [80].
Conclusion
In summary, metabolic and storage lung diseases consist of a
heterogeneous group of entities with diverse and interesting clin-
ical and imaging manifestations. Imaging findings can often be
invaluable in narrowing the differential diagnoses and pointing
towards a specific diagnosis in the right clinical setting. Also,
imaging tests such as HRCT have a pivotal role in assessing
disease progression and also in evaluating response to therapy.
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